K

Keymed Biosciences
2162

Latest price

Financial Snapshot

gainify

Market Data

Market Cap
HK$12.40B
EV
HK$10.91B
Shares Outstanding
275.60M
Beta
-0.03

Wall Street View

Analyst Rating
BUY
Analyst Target Price
HK$55.71
P/E 2025E
-
P/Revenue 2025E
16.89x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Keymed Biosciences Inc.

gainify

K

Keymed Biosciences Inc.

2162

Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD...

Sector

Healthcare

Industry

Biotechnology

CEO

Chen, Bo

Employees

1,258

IPO Date

2021-07-08

Headquarters

Building D2, No. 18 BioTown Middle Road, Tianfu International BioTown, Shuangliu District, Chengdu, Sichuan Province, 610219, China

gainify
mailcontactcontact
powered-by-sp

NEWSLETTER

COMPANY

© Copyright 2025, All Rights Reserved